Pancreatic Cancer

Pancreatic Cancer

Despite decades of intensive efforts to discover and develop an effective therapy, pancreatic ductal adenocarcinoma (PDAC), which accounts for 80–90% of pancreatic neoplasms worldwide, remains one of the leading causes of cancer-related death. Treatment and prevention of PDAC therefore constitute major unmet needs that can be addressed by establishing a better understanding of this disease at the molecular level.

By developing new models that more accurately recapitulate the pathological manifestations, molecular profiles, clinical relapse processes, and other features specific to human cancers, we have successfully engineered several lines of models for PDAC and other tumors. Based on these models as well as patient-derived PDAC cells obtained through collaborative research with academia and clinicians, we continue to seek out therapeutic targets and novel therapeutic concepts that could bring hope to patients living with advanced-stage, terminal forms of cancers.

Ken SASAI, Ph.D.mail
Principal Scientist

RESEARCH